This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to ...

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...

Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of ...

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson’s rating is ...

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...

Medtronic announced today that it received CE mark approval for its Evolut FX+ transcatheter aortic valve implantation (TAVI) ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...

Beese Fulmer Investment Management Inc. cut its position in Medtronic plc (NYSE:MDT – Free Report) by 24.4% during the third ...